{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-003383","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2023-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.984370+00:00","generated_at":"2026-06-17T18:33:33.836334+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Monopar FY2022 net loss $10.5M; Validive interim readout due next week; camsirubicin dose-escalation continues","bullets":["Net loss FY2022 $10.5M ($0.83/share) vs $9.1M ($0.73/share) in 2021; cash $13.1M.","Validive Phase 2b/3 VOICE trial interim analysis go/no-go readout expected by end of next week.","Camsirubicin Phase 1b enrolling 5th dose level (650 mg/m²); no cardiotoxicity, 75% no hair loss.","CFO Kim Tsuchimoto appointed to board; board size increased to six.","Current funds expected to cover camsirubicin topline results by end 2023; additional funding sought within 12 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-003383","json":"https://secwatch.observer/filing/0001654954-23-003383.json","markdown":"https://secwatch.observer/filing/0001654954-23-003383.md","text":"https://secwatch.observer/filing/0001654954-23-003383.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000165495423003383/0001654954-23-003383-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000165495423003383/mnpr_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T18:33:33.836334+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"472b9626c8cb5434cdbc97f060ba3be2fab8d22b","claim":"Monopar Therapeutics reported financial results for fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"On March 23, 2023, Monopar Therapeutics Inc. issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495423003383/0001654954-23-003383-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}